10-Q: NextCure Announces Merger, Restructuring, and Q2 2026 Results

NextCure, Inc. reported its Q2 2026 results, detailing a significant net loss and substantial doubt about its going concern status, while simultaneously announcing a proposed merger with Avere Therapeutics and a comprehensive restructuring plan.

Summary

• NextCure, Inc. reported a net loss of $14.9 million for the three months ended June 30, 2026, and $24.7 million for the six months ended June 30, 2026.
• The company has substantial doubt regarding its ability to continue as a going concern, with cash and cash equivalents and marketable securities of $20.1 million expected to last into the fourth quarter of 2026.
• A definitive merger agreement was entered into with Avere Therapeutics, Inc. on July 14, 2026, with the combined company expected to operate as Avere Therapeutics, Inc. and trade under the ticker symbol 'AVRX'.
• Concurrently with the merger, a private financing is expected to generate approximately $320 million in gross proceeds.
• The company announced a restructuring and workforce reduction plan, impacting a substantial majority of its workforce, with expected charges of approximately $2.4 million.
• Further lease terminations were executed in July and August 2026, reducing leased premises by approximately 39,432 square feet.
• An asset sale to Xcellon Biologics, LLC for approximately $0.5 million was completed on July 31, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the substantial doubt about the company's ability to continue as a going concern, significant operating losses, and the uncertainty surrounding the proposed merger and its impact on future operations.

Positives

• The proposed merger with Avere Therapeutics and concurrent private financing are expected to provide significant capital to the combined company, potentially alleviating going concern issues.
• The company is actively seeking to monetize legacy assets through partnerships, licensing, or sales, which could provide future value.
• The SIM0505 program showed promising interim Phase 1 data with an objective response rate of 55% in evaluable gynecologic cancer patients within the therapeutic dose range.
• The company has a strong focus on advancing innovative medicines for cancer patients who do not respond to current therapies.

Negatives

• A net loss of $14.9 million was reported for Q2 2026, and $24.7 million for the first six months of 2026.
• Substantial doubt exists regarding the company's ability to continue as a going concern, with cash reserves projected to last only into Q4 2026 without additional funding.
• Significant operating losses and an accumulated deficit of $461 million have been incurred since inception.
• The company has discontinued further investment in the LNCB74 co-development program.
• The SIM0505 clinical trial sites were instructed to stop screening, consenting, enrolling, and delivering first doses to new patients.
• A substantial workforce reduction is planned as part of the restructuring.
• The merger is subject to customary closing conditions and stockholder approval, with no guarantee of completion.
• Contingent Value Rights (CVRs) for legacy NextCure assets may expire valueless if no qualifying proceeds are received.

Risks

• The proposed merger with Avere Therapeutics may not be completed on the currently contemplated terms or within the expected timeframe, or at all, which could adversely affect the business, financial condition, and results of operations.
• The private placement financing to be completed concurrently with the Merger may not be completed on the currently contemplated terms or at all, and may result in significant dilution.
• Even if the Merger is completed, the combined company may incur losses for the foreseeable future and might never achieve or sustain profitability.
• Stockholders may not receive any payment on the CVRs, and the CVRs may expire valueless.
• The company's future operations are highly dependent on the closing of the Merger, and if it is not consummated, substantial additional funding would be required.
• If the Merger is not completed, the company may decide to pursue a dissolution and liquidation, in which case it is unlikely that substantial resources would be available for distribution to stockholders.
• The company's ability to continue operations and satisfy its obligations will depend on its ability to successfully execute its strategic plans and obtain additional sources of capital if needed.
• Changes in international relations, tariffs, and other trade regulations between the U.S. and China could impact the company.

Future Outlook

The company expects to continue generating operating losses for the foreseeable future. Its future liquidity strategy and capital requirements are expected to be substantially impacted by the outcome of the proposed merger with Avere Therapeutics and the concurrent private financing. Without the merger, the company expects its current cash and marketable securities to fund operations into the fourth quarter of 2026, after which substantial additional funding would be required.

Management Comments

• Management believes its cash and cash equivalents and marketable securities of $20.1 million as of June 30, 2026 will be sufficient to fund the Company's operations into the fourth quarter of 2026.
• The Company's expectation to generate negative operating cash flows in the future and the need for additional funding to support its planned operations raise substantial doubt regarding the Company's ability to continue as a going concern.
• Management's plans to alleviate the conditions that raise substantial doubt include completing the proposed merger with Avere Therapeutics, implementing restructuring activities designed to reduce operating expenditures, and pursuing partnership, licensing, sale and other opportunities to advance or monetize its legacy assets.
• The Company intends to execute its strategic plan, including completing the proposed merger transaction, restructuring its activities, managing its legacy assets and obligations and seeking to monetize its legacy programs and intellectual property.

Industry Context

StockSavvy.ai notes that NextCure's situation is not uncommon for clinical-stage biopharmaceutical companies heavily reliant on external funding. The proposed merger with Avere Therapeutics, focusing on oral therapies for inflammatory diseases, represents a strategic pivot, potentially shifting the combined entity's focus away from NextCure's legacy oncology pipeline.

Comparison to Industry Standards

• The net loss of $14.9 million for the quarter and $24.7 million for the six months is substantial for a clinical-stage company, but not entirely out of line with peers facing lengthy development cycles and high R&D costs.
• The cash runway into Q4 2026 with $20.1 million in cash and equivalents is a critical concern, as many biotechs aim for a 12-18 month runway to provide sufficient time for development and financing.
• The decision to stop new patient enrollment in the SIM0505 trial and to cease co-funding LNCB74 reflects a strategic shift often seen when a company is undergoing significant corporate events like a merger or facing severe liquidity constraints.
• The proposed merger with Avere Therapeutics, which is expected to own the substantial majority of the combined company, is a common strategy for smaller companies to gain access to capital and a more focused development pipeline.

Legal Proceedings

• The company is not currently a party to any litigation or legal proceeding, nor is management aware of any pending or threatened litigation that is likely to materially affect the company's business or financial results.

Related Party Transactions

• On June 13, 2025, the Company entered into a License Agreement with Simcere Zaiming Pharmaceutical Co., Ltd. (Zaiming) and a Subscription Agreement with Simcere Zaiming, Inc. (an affiliate of Zaiming) for the private placement of $2.0 million of common stock.
• The merger agreement with Avere Therapeutics includes a contingent value rights (CVR) arrangement for existing NextCure stockholders tied to the potential future monetization of certain legacy NextCure assets.

Stakeholder Impact

• Shareholders face significant uncertainty regarding the completion of the merger and the potential value of CVRs tied to legacy assets, with a risk of losing their investment if the merger fails and liquidation occurs.
• Employees face significant impact due to a planned substantial workforce reduction.
• Creditors and suppliers may face uncertainty regarding payment if the company's going concern status is not resolved.
• Licensors and collaborators (e.g., Zaiming, LigaChem) are impacted by the strategic shifts, with NextCure ceasing co-funding for LNCB74 and seeking to monetize SIM0505 rights.

Next Steps

• Complete the proposed merger with Avere Therapeutics, Inc.
• Implement restructuring and workforce reduction plan.
• Seek opportunities to partner, license, or monetize legacy assets.
• Transition patients from the SIM0505 study to alternative therapies.
• Support LigaChem Biosciences in the transfer of LNCB74 program materials.
• Account for lease terminations in the quarter ending September 30, 2026.
• Complete the sale of certain assets to Xcellon Biologics, LLC.

Key Dates

Recommendation

The proposed merger with Avere Therapeutics and the concurrent $320 million financing offer a potential lifeline and a path to future development, but significant execution risks remain. The substantial net losses, going concern doubts, and the uncertainty of merger completion and CVR value warrant a cautious 'hold' stance. Investors should monitor the merger's progress and the combined entity's strategy post-completion.

Keywords

biopharmaceutical, clinical-stage, cancer therapy, antibody-drug conjugate, merger, restructuring, going concern, drug development